Dongmai Roadshow Hall Phase II Showcases Five Innovative Healthcare Projects

It has been one week since the inaugural premium launch of the “Artery Roadshow Hall.” Within this period, we received applications from more than 10 innovative companies/projects to join the hall and facilitated in-depth discussions with over 30 investment institutions. In addition to the projects featured in the first roadshow, 60% of the financing-seeking innovative projects connected through VCBeat are maintaining ongoing contact with investment institutions.

Meanwhile, we are also identifying more high-quality projects and enterprises. Through in-depth discussions with the editorial team of the Content Center this week, we have carefully selected five premium projects to be featured in the second session of the “VB Roadshow Hall.”

Julu Medical is a rehabilitation service operations company dedicated to building a systematic framework for “comprehensive rehabilitation, specialized integration, and the diagnosis and treatment of cardiopulmonary chronic diseases.” By integrating high-quality medical rehabilitation resources from both domestic and international sources, it provides holistic solutions for comprehensive rehabilitation, specialized integration, and cardiopulmonary chronic disease rehabilitation to partner hospitals, health examination centers, nursing homes, and other institutions. The company comprehensively advances the establishment of cardiopulmonary chronic disease rehabilitation centers through initiatives such as developing management service systems for cardiopulmonary chronic disease rehabilitation, integrating and researching related medical equipment, and providing professional training for cardiopulmonary physical therapists. It has also established academic exchanges and learning collaborations with experts from Xiangya Hospital, Fuwai Hospital, Peking University Third Hospital, Beijing Anzhen Hospital, China-Japan Friendship Hospital, Beijing Rehabilitation Hospital, and Guangdong Provincial Hospital of Chinese Medicine.

The company currently operates six “Julu Cardiopulmonary Chronic Disease Rehabilitation Centers.” The centers’ teams of rehabilitation physicians, cardiopulmonary physical therapists, and exercise therapists have repeatedly participated in academic exchanges with internationally renowned cardiopulmonary rehabilitation institutions, including the Mayo Clinic Cardiac Rehabilitation Center (USA), KU Leuven (Belgium), and the University of Sydney (Australia), to learn and promote advanced international practices in cardiopulmonary rehabilitation.

Enterprise Tags: Rehabilitation Chronic Disease Management

Financing Plan

Funding Amount: RMB 30 Million (Current Round)

Financing History:

Financing Round 1: Angel Round

Funding Amount: Tens of millions of RMB (Danen Capital)

Financing Round 2: Series A

Funding Amount: Tens of Millions of RMB (Mifang Capital, Tianyi Group, Dan'en Capital)

Related Links:

1. “Julu Medical Secures Tens of Millions in Series A Funding Led by Mifang Capital, Driving the Practical Implementation of Cardiopulmonary Rehabilitation”

https://vcbeat.top/ZmFlNTdlMTNhOWUwOTA0NDUzZTk3NmI5MDhlYTBkM2Q=

2. “Addressing Pain Points in Talent, Equipment, and Operational Systems: Julu Medical Management Creates a One-Stop Solution to Promote the Implementation of Cardiopulmonary Rehabilitation”

https://vcbeat.top/Mjk1Zjg0ZDRlZDYyODYyODI1OTUwZDMyNTY5YTQ5MWU=

As a rehabilitation system support and operations provider, Julu Medical Management focuses on modern rehabilitation integrated with traditional methods. It specializes in delivering a comprehensive cardiopulmonary chronic disease rehabilitation management system to hospitals and nursing homes, comprising talent training, product R&D, and a cardiopulmonary rehabilitation management platform. This has culminated in Julu’s proprietary 5P3S1C framework, tailored specifically for the Chinese context. Currently, China’s rehabilitation medical market is valued at approximately RMB 20 billion (around RMB 15 per capita). In comparison, the U.S. rehabilitation medical market stands at USD 20 billion (around USD 80 per capita, excluding long-term care) or USD 200 billion (around USD 800 per capita, including long-term care), indicating substantial room for growth in China. Particularly, hundreds of millions of chronic disease patients have needs for visceral rehabilitation; however, the market remains in its nascent stage, with future market size expected to exceed RMB 100 billion.

Wuhan Langdi Telemedicine Technology Co., Ltd. is a high-tech enterprise specializing in telemedicine and one-stop medical informatization solutions, integrating R&D, production, and sales.

Wuhan Langdi has collaborated closely with the Health Electronics R&D Center of the Institute of Microelectronics, Chinese Academy of Sciences, and the Chronic Disease Monitoring and Prevention Engineering Technology Center of the IoT Research and Development Center, Chinese Academy of Sciences, achieving breakthrough progress in the field of remote mobile healthcare. The company’s main product that has been approved and put into production—the Zhongke Xindian LDE Series Remote Real-Time Dynamic ECG Monitor—is the only product capable of simultaneously meeting four key criteria: dynamic monitoring, real-time analysis, early warning, and remote diagnosis.

Enterprise Tags: Telemedicine, MedTech, ECG Big Data

Financing Information

Financing Plan

Funding Round: Series A+ (Current Round)

Financing Amount: 60 million

Diluted Equity Ratio: 15%-20%

Financing History

Funding Round 1: Series A

Financing Amount: RMB 20 Million (Three Gorges Huaxiang)

Related Links:

“Leveraging ECG monitoring devices, Wuhan Langdi aims to establish China’s ECG information database”

https://vcbeat.top/NWIyOTJhYzU2OTRkYjgxODczNDEzMzMyMWMxMWUxNjI=

Langdi’s core competitive advantage lies in its electrocardiogram (ECG) information database. While the market is saturated with hardware products for ECG monitoring, individual devices are highly susceptible to substitution by similar offerings. By prioritizing the development of its database, Langdi has established regional ECG information databases and monitoring platforms through collaborations with government agencies, top-tier cardiovascular hospitals, and leading physicians in China. This strategic approach has enabled the company to secure critical medical resources, thereby creating an irreplaceable competitive edge.

Senmei Medical, headquartered in the Liangjiang New Area of Chongqing, is a technology company dedicated to clinical condition management solutions. By restructuring the foundation of in-hospital structured medical record data and establishing an out-of-hospital real-world structured channel, Senmei enables clinical visibility and management of out-of-hospital behaviors while providing patients with clinical guidance outside the hospital. This achieves a closed-loop system for full-lifecycle disease management, thereby improving the quality of life for chronic disease patients. Building on its clinical collaboration operations, Senmei Medical is developing regional operational standards and scientific research data centers. This fosters cross-regional collaboration among hospitals at various levels within specialty alliances, creating a new healthcare service model that facilitates routine follow-ups and periodic condition assessments for patients. This approach promotes supply-side reform in healthcare, enhances patient care experiences, and balances interests among hospitals. Currently, in the Chongqing region, specialty alliances are led by aforementioned Grade A tertiary hospitals, with nine prefecture-level Grade A tertiary hospitals joining in the first phase. Following a trial run, participation will be gradually expanded; it is reported that the alliance may eventually include more than 30 public hospitals at Grade II Level A or above. This model is set to be replicated across all sample regions where Senmei Medical has established its presence nationwide.

Enterprise Tags: Chronic Disease Management, Artificial Intelligence

Financing Plan

Funding Round: Angel Round (Current)

Financing Amount: RMB 8–10 million

Diluted Equity Ratio: TBD

Related Links:

“Onboarding One Grade-A Tertiary Hospital Every Two Weeks on Average: How Senmei Medical Built Its Clinical Condition Management Platform”

https://vcbeat.top/MmYzMzAwOGQ3YzNiZGNiNGU1OWVjYmE1M2IzNmU5ZGM=

China’s healthcare system has long been centered on diagnosis and treatment. However, epidemiological surveys indicate that chronic diseases account for 86.6% of all-cause mortality and contribute to 70% of the disease burden, posing a severe societal challenge that demands urgent improvement. Senmei Medical has chosen to initiate its strategy through large tertiary hospitals. Chronic disease management requires systematic operations; given China’s national context, only large hospitals possess the resources and capabilities to develop standardized methodologies and achieve effective control, thereby gradually extending their expertise to secondary and even primary care institutions.

Meiqiao Technology is a dual-software enterprise and high-tech enterprise specializing in software R&D, production, sales, and services. It was the first company in China to focus on the development and service of intelligent software products for medical patients. The Aomi AI Medical Escort Service System leverages advanced real-time audio-visual interaction technology and autonomous learning capabilities of virtual robots, integrated with a vast medical service knowledge base. It addresses the "three longs and one short" service issues encountered by patients during medical visits, reducing time wasted on uninformed searches and unnecessary hospital stays (with 8.3 billion clinical visits recorded nationwide in China in 2018). This mobile, one-stop, end-to-end service covers pre-consultation, during-consultation, and post-consultation phases, enabling direct conversation with virtual robots through user-friendly, intuitive operations. It breaks down traditional information silos in healthcare services, achieves real-time sharing of information between doctors and patients, and supports closed-loop hospital management and smart hospital accreditation.

Enterprise Tags: AI Medical Escort, AI Inquiry Kiosk, AI Triage Robot, 3D Intelligent Tax Robot

Financing Plan

Financing Round: Series A (Current Round)

Financing Amount: RMB 30–50 million

Diluted Equity Stake: 15%-25%

Project Highlights: Meiqiao currently holds 38 software copyrights and 12 invention patents. The preliminary R&D of these invention patents has successfully yielded the following: the “Aomi” AI Medical Companion System, which provides end-to-end guidance for patients seeking medical care; the “Aoxun” Inquiry Kiosk, which automatically answers customer queries; the “Aomi” Virtual Customer Service Product for portal websites; the “Aomi” Intelligent Service Platform for user smart search and service acquisition; and the 3D Intelligent Tax Robot, designed to serve taxpayers and tax administration personnel.

The company’s smart patient service products have been successfully implemented in nearly 70 hospitals across 14 provinces and municipalities in China, with typical clients including Jiangsu Province People’s Hospital, Wuxi People’s Hospital, and the PLA No. 302 Hospital. The 3D Tax Robot has been deployed in tax service halls in several provinces across China.

Ningbo Yuefan Medical Technology Co., Ltd. specializes in the research and development of interactive, targetable neuromodulation medical products. Through cross-disciplinary technological innovation, the company has secured extensive intellectual property rights and international medical certifications in the non-pharmacological treatment of primary headaches and the non-pharmacological relief of motion sickness, currently holding a leading position globally. Its anti-emetic device is designed to prevent and alleviate motion-induced vomiting (including seasickness, carsickness, VR-induced dizziness, and altitude sickness), pregnancy-related vomiting, and drug-induced vomiting (such as that caused by chemotherapy and post-operative conditions). The headache relief patch is the world’s first disposable wearable device capable of alleviating drowsiness, migraines, insomnia, and depression.

Within three years, the WAT Med project has achieved cumulative industrialized sales exceeding RMB 15 million, completed a RMB 3 million angel financing round, and the team is actively preparing for the Pre-A round to expand its market scale.

Corporate Tags: Targeted Neuromodulation, Neurostimulation, Non-Pharmacological Therapy

Financing Plan

Funding Round: Pre-A

Financing Amount: 10 million

Diluted Equity Ratio: TBD

Financing History

Funding Round: Angel Round

Financing Amount: RMB 3 million

Related Links:

“Returnee team focuses on targeted neuromodulation, with antiemetic and analgesic products sold in over 30 countries”

https://vcbeat.top/NmQ3ZTFiNGY3N2MyMGU4NzNhY2VlNTg2MzU0ZWUwNmY=

There is a substantial body of research and clinical application data in the field of neuromodulation therapy. Its therapeutic mechanisms and modalities differ significantly from those of pharmacological treatments. Compared with medication, neuromodulation therapy can avoid issues such as drug addiction and adverse drug reactions. Yuefan Medical focuses on the research and development of innovative home-use medical devices, adopting a strategy of developing one product for each specific symptom. These devices are simple to operate, eliminating concerns about parameter adjustment and portability. Examples include an anti-emetic device resembling a wristband and a headache relief patch similar to an adhesive bandage. Yuefan Medical has currently achieved notable success in the non-pharmacological management of vomiting and migraine.

Above is the company information for the second session of the “Artery Roadshow Hall.” For business plans and other related information, please contact Xiao Yun at VCBeat (WeChat ID: DongMai_Investent). If you are an innovator in the healthcare industry seeking opportunities, we welcome you to reach out. We look forward to connecting with like-minded individuals.